Viagra daily small dose may reduce the risk of colorectal cancer

Share This Post

Scientists report that a small daily dose of Viagra can significantly reduce the risk of colorectal cancer in animal models, which is the third leading cause of cancer death.

Dr. Darren D. Browning, a cancer researcher at the Georgia Cancer Center and the Department of Biochemistry and Molecular Biology, said that Viagra can reduce the formation of polyps in half. Polyps are an abnormal intestinal lining cell cluster and are often asymptomatic, but polyps have The possibility of becoming cancer.

Viagra can inhibit the naturally occurring enzyme PDE5 in colon cells and other decomposable circulating GMP tissues, so it can be used to reduce cell proliferation and improve cell differentiation, such as goblet cells secreting protective mucus. The study found that targeting circulating GMP signaling seems to be a good prevention strategy for high-risk patients.

The study found that placing Viagra in the drinking water of mice reduced polyps in the mouse model, and the mice had genetic mutations in adenomatous polyposis coli (APC). Like these mice, people with  mutations in the APC gene can develop into hundreds or thousands of polyps in the colon and rectum, and ultimately eventually cause colorectal cancer. At the same time, giving Viagra to young mice can reduce the number of tumors in these animals by half.

He pointed out that Viagra has been on the market for many years and is known for its ability to relax smooth muscle cells around blood vessels. It is used in people with multiple doses and age groups, from patients with premature pulmonary hypertension to elderly people with erectile dysfunction. Dr. Browning said that the next step should include clinical trials of drugs in people at high risk for colorectal cancer, such as those with a strong family history, multiple polyps, and chronic intestinal inflammation such as colitis. If the test achieves gratifying results, Viagra will refresh the indications for cancer prevention.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy